Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study

Source: Article title. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study

Source: Article title.

The patients were thereafter followed using mailed out biannual follow-up questionnaires for up to 15 years postoperatively.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study

Cohort study · Cancer Causes & Control · 2024

Original publication title

Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study

Hampus Lindgren; David Ademi; Christopher Godina; Helga Tryggvadottir; Karolin Isaksson; Helena Jernström

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

VDR genotypes were associated with breast cancer prognosis and the association might be modified by tumor size. Further research is needed to confirm the findings and elucidate their potential clinical implications.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Vitamin D has some anticancer properties that may decrease breast cancer risk and improve prognosis. The aim was to investigate associations between four previously studied VDR SNPs (Taq1, Tru91, Bsm1, and Fok1) and prognosis in different groups of breast cancer patients.

Source: Purpose

Abstract: What methods does the paper describe?

VDR genotyping of 1,017 breast cancer patients included 2002 to 2012 in Lund, Sweden, was performed using Oncoarray. Follow-up was until June 30, 2019. Clinical data and patient information were collected from medical records and questionnaires. Cox regression was used for survival analyses.

Source: Methods

Abstract: Results

Genotype frequencies were as follows: Fok1 (AA 15.7%, AG 49.1%, GG 35.1%), Bsm1 (CC 37.2%, CT 46.1%, TT 16.7%), Tru91 (CC 77.8%, CT 20.7%, TT 1.5%), and Taq1 (AA 37.2%, AG 46.2%, GG 16.6%). During follow-up there were 195 breast cancer events. The homozygous variants of Taq1 and Bsm1 were associated with reduced risk of breast cancer events (adjusted HR = 0.59, 95% CI 0.38 to 0.92 for Taq1 and adjusted HR = 0.61, 95% CI 0.40 to 0.94 for Bsm1). The G allele of the Fok1 was associated with increased risk of breast cancer events in small tumors (pT1, adjusted HR = 1.83, 95% CI 1.04 to 3.23) but not in large tumors (pT2/3/4, adjusted HR = 0.80, 95% CI 0.41 to 1.59) with a borderline interaction (Pinteraction = 0.058).

No interactions between VDR genotypes and adjuvant treatments regarding breast cancer prognosis were detected.

Source: Results

Abstract: Conclusion

VDR genotypes were associated with breast cancer prognosis and the association might be modified by tumor size. Further research is needed to confirm the findings and elucidate their potential clinical implications.

Source: Conclusion
Authors’ abstract

Purpose

Vitamin D has some anticancer properties that may decrease breast cancer risk and improve prognosis. The aim was to investigate associations between four previously studied VDR SNPs (Taq1, Tru91, Bsm1, and Fok1) and prognosis in different groups of breast cancer patients.

Methods

VDR genotyping of 1,017 breast cancer patients included 2002 to 2012 in Lund, Sweden, was performed using Oncoarray. Follow-up was until June 30, 2019. Clinical data and patient information were collected from medical records and questionnaires. Cox regression was used for survival analyses.

Results

Genotype frequencies were as follows: Fok1 (AA 15.7%, AG 49.1%, GG 35.1%), Bsm1 (CC 37.2%, CT 46.1%, TT 16.7%), Tru91 (CC 77.8%, CT 20.7%, TT 1.5%), and Taq1 (AA 37.2%, AG 46.2%, GG 16.6%). During follow-up there were 195 breast cancer events. The homozygous variants of Taq1 and Bsm1 were associated with reduced risk of breast cancer events (adjusted HR = 0.59, 95% CI 0.38 to 0.92 for Taq1 and adjusted HR = 0.61, 95% CI 0.40 to 0.94 for Bsm1). The G allele of the Fok1 was associated with increased risk of breast cancer events in small tumors (pT1, adjusted HR = 1.83, 95% CI 1.04 to 3.23) but not in large tumors (pT2/3/4, adjusted HR = 0.80, 95% CI 0.41 to 1.59) with a borderline interaction (Pinteraction = 0.058).

No interactions between VDR genotypes and adjuvant treatments regarding breast cancer prognosis were detected.

Conclusion

VDR genotypes were associated with breast cancer prognosis and the association might be modified by tumor size. Further research is needed to confirm the findings and elucidate their potential clinical implications.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10552-023-01845-1.

Publication and source details

Original title: Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study

Hampus Lindgren; David Ademi; Christopher Godina; Helga Tryggvadottir; Karolin Isaksson; Helena Jernström

Cancer Causes & Control · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100009780Region SkåneST ALFYoung researcher awardALF 40620Tryggvadottir Helga Isaksson Karolin Jernström Helena http://dx.doi.org/10.13039/501100011077Skånes universitetssjukhushttp://dx.doi.org/10.13039/501100002794CancerfondenCAN 20 0763Jernström Helena http://dx.doi.org/10.13039/501100004635Fru Berta Kamprads Stiftelsehttp://dx.doi.org/10.13039/501100006738Medicinska Fakulteten, Lunds UniversitetLund University

Open access funding provided by Lund University.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:27:15.240843+00:00

DOI: 10.1007/s10552-023-01845-1 · PMC11130020